Date: 2012-09-18
Type of information: Grant
Company: Mutabilis (France)
Investors:
Amount: € 4 million
Funding type: grant
Planned used: This grant will be used to fund the HIVINNOV project, which is aimed at developing new antiretrovirals against HIV. Mutabilis is the coordinator of the project as well as a partner in it.
Others: Mutabilis, a subsidiary of Pharma Omnium International specialized in the discovery of new therapeutic approaches for treating serious, hospital-acquired infections, has formed a consortium in July 2011 comprising five prestigious European academic research establishments that are regarded as world leaders in the field of virus-host cell interactions in the area of HIV. They are the following: University College London (UCL) and the Cancer Research Institute UK (CRUK) in the United Kingdom; the Academic Medical Center of the University of Amsterdam (AMC) in the Netherlands; the AIDS Units Clinical Institute of the University of Barcelona (FCRB) in Spain and a group of two French research establishments – the Institut Cochin, which is run jointly by the National Institute of Health and Medical Research (INSERM), the National Scientific Research Center (CNRS) and the University of Paris Descartes) and the University Hematology Institute (IUH) of the Saint Louis Hospital in Paris (run by INSERM, the CNRS and the University of Paris Diderot)
The project, known as “Generation of a new class of antiretrovirals targeting HIV-cellular cofactors interactions”, entails the development of new anti-HIV antiretrovirals up to the Phase IIa clinical trial stage. The particular feature of these new antiretrovirals is that they do not target the virus directly, as the majority of existing antiretrovirals do, but the interactions between the virus and its host, which are essential for the replication of the virus. The project, which will get under way in October when a launch meeting is to be held at the Biocitech science and technology park, is due to last three years and to receive total funding of € 6 million.
Therapeutic area: Infectious diseases
